Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.57 |
| ▸ | CXCR4 | P61073 | 7/20 | 0.47 |
| ▸ | GLS | O94925 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.45 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.45 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.45 |
| ▸ | CCR2 | P41597 | 1/20 | 0.45 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.45 |
| ▸ | BLM | P54132 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.45 |
| ▸ | CHRM3 | P20309 | 9/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3340879 | 0.85 | PRMT6 (0.57) | TDP1HRH3 | |
| SCHEMBL29442395 | 0.85 | PRMT6 (0.57) | TDP1HRH3 | |
| SCHEMBL19066609 | 0.84 | SIGMAR1 (0.57) | SIGMAR1CXCR4MEN1CHRM2CHRM1 | |
| SCHEMBL31528239 | 0.84 | SMN1; SMN2 (0.58) | TDP1HRH3 | |
| SCHEMBL7656309 | 0.84 | SMN1; SMN2 (0.58) | TDP1HRH3 | |
| Hydrochloric Acid SCHEMBL9051088 | 0.83 | SIGMAR1 (0.56) | SIGMAR1CXCR4MEN1CHRM2CHRM1 | |
| SCHEMBL208910 | 0.83 | NCF1 (0.62) | CXCR4HRH3 | |
| SCHEMBL31528286 | 0.83 | NCF1 (0.62) | CXCR4HRH3 | |
| SCHEMBL1259602 | 0.81 | SIGMAR1 (0.71) | SIGMAR1CXCR4MEN1CHRM2CHRM1 | |
| SCHEMBL21961925 | 0.81 | SIGMAR1 (0.71) | SIGMAR1CXCR4MEN1CHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210085649-A1 | METHODS AND USE OF COMPOUNDS THAT BIND TO RELA OF NF-KB | CEDARS-SINAI MEDICAL CENTER (US) | 2021-03-25 | — | — | US | disclosed |
| US-10881641-B2 | Methods and use of compounds that bind to RelA of NF-kB | CEDARS-SINAI MEDICAL CENTER (US) | 2021-01-05 | — | — | US | disclosed |
| US-20180078528-A1 | METHODS AND USE OF COMPOUNDS THAT BIND TO RELA OF NF-KB | CEDARS-SINAI MEDICAL CENTER (US) | 2018-03-22 | — | — | US | disclosed |
| US-9637491-B2 | Pyrazolo[4,3-D]pyrimidines as kinase inhibitors | ORIGENIS GMBH (DE) | 2017-05-02 | — | — | US | disclosed |
| US-20150266882-A1 | PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2015-09-24 | — | — | US | disclosed |
| WO-2014060112-A1 | PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2014-04-24 | — | — | WO | disclosed |
| WO-2011094890-A1 | PHENYLALANINE DERIVATIVES AND THEIR USE AS NON-PEPTIDE GLP-1 RECEPTOR MODULATORS | ARGUSINA INC. (US) | 2011-08-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180078528-A1 | METHODS AND USE OF COMPOUNDS THAT BIND TO RELA OF NF-KB | NFKBIA, RELA, NFKB1 | SIGMAR1 4074/4885CXCR4 1212/4885GLS 3861/4885 |
| US-20150266882-A1 | PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS | LRRK2, MYLK2, MYLK | SIGMAR1 4764/4885CXCR4 2591/4885GLS 1413/4885 |
| US-10881641-B2 | Methods and use of compounds that bind to RelA of NF-kB | NFKBIA, RELA, NFKB1 | SIGMAR1 4074/4885CXCR4 1212/4885GLS 3861/4885 |
| US-20210085649-A1 | METHODS AND USE OF COMPOUNDS THAT BIND TO RELA OF NF-KB | NFKBIA, RELA, NFKB1 | SIGMAR1 4074/4885CXCR4 1212/4885GLS 3861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.